Combinatory anti-tumor activities of AQ4 and temsirolimus against colorectal cancer cells
Authors:
Preprint
- 24 August 2022
- preprint
- Published by Springer Nature in Research Square
Abstract
Purpose: Banoxantrone is a topoisomerase II inhibitor that is selectively activated in hypoxia. Although it has exhibited anti-tumor activity against several types of cancers in preclinical models, its efficacy against colorectal cancer (CRC) remains unclear.Methods: We examined the antitumor effects of AQ4, an activated metabolite of banoxantrone, in CRC cell lines (HT-29, CaR-1) using in vitro experiments under normoxic and hypoxic conditions. The inhibition of cell growth was assessed using a proliferation assay. The induction of apoptosis and changes in the cell cycle were measured using flow cytometry. Signaling pathways involved in apoptosis and hypoxia were analyzed. The anti-tumor activity of temsirolimus, an inhibitor of mammalian target of rapamycin, and the combined effects of temsirolimus and AQ4 were also evaluated.Results: Regardless of the oxygen condition, a single drug treatment with AQ4 or temsirolimus inhibited proliferation and induced apoptosis in both cell lines, accompanied by a reduction in the phosphorylation of S6. AQ4 induced G2/M cell cycle arrest, whereas temsirolimus induced G0/G1 arrest. Moreover, the combined treatment markedly reduced the proportion of cells in the S phase and enhanced apoptosis, as evidenced by an increased Bax/Bcl-2 ratio. The hypoxia-induced activation of the HIF-1α pathway was suppressed by AQ4 and temsirolimus.Conclusion: Based on the cooperative anti-tumor activity of AQ4 and temsirolimus in vitro, the combination of banoxantrone plus temsirolimus has potential as a treatment option for CRC in preclinical and clinical settings.Keywords
All Related Versions
This publication has 24 references indexed in Scilit:
- p53/TAp63 and AKT Regulate Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling through Two Independent Parallel Pathways in the Presence of DNA DamageJournal of Biological Chemistry, 2014
- mTOR is a key modulator of ageing and age-related diseaseNature, 2013
- mTOR Inhibitors and its Role in the Treatment of Head and Neck Squamous Cell CarcinomaCurrent Treatment Options in Oncology, 2012
- Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumorsCancer Letters, 2011
- Mitoxantrone Inhibits HIF-1α Expression in a Topoisomerase II–Independent PathwayClinical Cancer Research, 2011
- ERK and cell death: Mechanisms of ERK‐induced cell death – apoptosis, autophagy and senescenceThe FEBS Journal, 2009
- Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1α involvement in CYP3A4 repressionEuropean Journal of Cancer, 2009
- Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic CancerClinical Cancer Research, 2007
- Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor TemsirolimusCancer Research, 2006
- Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agentCancer and Metastasis Reviews, 1993